Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

57.03 +3.73 (+7.00%)
Streaming Delayed Price Updated: 12:33 PM EST, Feb 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Participate in March Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
Via Investor Brand Network
Topics Intellectual Property
News headline image
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
From BioMedWire
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces Third Quarter 2025 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
From Biogen Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Participate in September Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces Second Quarter 2025 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- to... 
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
From Supernus Pharmaceuticals, Inc.; Sage Therapeutics, Inc.
Via GlobeNewswire
News headline image
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals
New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay’s ADHD symptom management 
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces Paragraph IV ANDA Filings for Qelbree®
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces First Quarter 2025 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus to Participate in Two Upcoming Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.